PMID- 32311201
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20210831
IS  - 1442-9071 (Electronic)
IS  - 1442-6404 (Linking)
VI  - 48
IP  - 6
DP  - 2020 Aug
TI  - iStent inject trabecular micro-bypass stents with topical prostaglandin as 
      standalone treatment for open-angle glaucoma: 4-year outcomes.
PG  - 767-774
LID - 10.1111/ceo.13763 [doi]
AB  - IMPORTANCE: Long-term data are needed regarding effective and safe glaucoma 
      treatment modalities. BACKGROUND: This study evaluated 4-year outcomes of 
      second-generation trabecular micro-bypass stent implantation (iStent inject) 
      combined with topical travoprost in open-angle glaucoma (OAG). DESIGN: 
      Prospective, non-randomized, multi-surgeon study at a tertiary care ophthalmology 
      centre. PARTICIPANTS: OAG subjects with preoperative intraocular pressure (IOP) 
      18 to 30 mmHg on two medications and 22 to 38 mmHg post-washout. METHODS: 
      Subjects (n = 53) underwent standalone iStent inject implantation and started 
      travoprost on postoperative Day 1. Measures included IOP, medications, 
      comprehensive ophthalmic examinations and testing, and adverse events (AEs). 
      Annual medication washouts were performed. MAIN OUTCOME MEASURES: Mean medicated 
      and unmedicated IOP; and proportions of eyes with IOP </=18mmHg, </=15 mmHg, or >/=20% 
      reduced while on travoprost vs screening IOP on two medications. RESULTS: At 
      48 months postoperative, 85% of eyes reduced IOP >/=20% on travoprost vs screening 
      IOP on 2 medications; 92% of eyes had IOP </=18 mmHg on travoprost; and 83% had IOP 
      </=15 mmHg on travoprost. At Month 49 (post-washout), 90% of eyes reduced IOP >/=20% 
      vs preoperative washout IOP. Throughout follow-up, mean IOP on travoprost was 
      11.9 to 13.0 mmHg (34%-40% reduced vs 19.7 mmHg on 2 medications preoperatively; 
      P < .0001 throughout), and post-washout IOP was 16.5 to 17.7 mmHg (28%-34% 
      reduced vs 24.9 mmHg preoperatively; P < .0001 throughout). Favourable safety 
      included minimal AEs; stable visual acuity, cup-to-disc ratio and visual fields; 
      and no secondary surgeries. CONCLUSIONS AND RELEVANCE: Combining iStent inject 
      implantation with topical prostaglandin produced significant and safe 4-year IOP 
      and medication reductions in OAG.
CI  - (c) 2020 Royal Australian and New Zealand College of Ophthalmologists.
FAU - Berdahl, John
AU  - Berdahl J
AUID- ORCID: 0000-0002-5468-7405
AD  - Vance Thompson Vision, Sioux Falls, South Dakota, USA.
FAU - Voskanyan, Lilit
AU  - Voskanyan L
AD  - S.V. Malayan Ophthalmology Centre, Yerevan, Armenia.
FAU - Myers, Jonathan S
AU  - Myers JS
AUID- ORCID: 0000-0002-8251-6750
AD  - Wills Eye Hospital, Jefferson Medical College, Philadelphia, Pennsylvania, USA.
FAU - Katz, L Jay
AU  - Katz LJ
AD  - Wills Eye Hospital, Jefferson Medical College, Philadelphia, Pennsylvania, USA.
AD  - Glaukos Corporation, San Clemente, California, USA.
FAU - Samuelson, Thomas W
AU  - Samuelson TW
AD  - Minnesota Eye Consultants, Minneapolis, Minnesota, USA.
LA  - eng
PT  - Journal Article
DEP - 20200512
PL  - Australia
TA  - Clin Exp Ophthalmol
JT  - Clinical & experimental ophthalmology
JID - 100896531
RN  - 0 (Prostaglandins)
SB  - IM
MH  - *Glaucoma, Open-Angle/diagnosis/drug therapy/surgery
MH  - Humans
MH  - Intraocular Pressure
MH  - Prospective Studies
MH  - Prostaglandins
MH  - Stents
OTO - NOTNLM
OT  - glaucoma
OT  - iStent inject
OT  - intraocular pressure
OT  - micro-invasive glaucoma surgery (MIGS)
OT  - prostaglandin
EDAT- 2020/04/21 06:00
MHDA- 2021/09/01 06:00
CRDT- 2020/04/21 06:00
PHST- 2019/12/30 00:00 [received]
PHST- 2020/04/01 00:00 [revised]
PHST- 2020/04/09 00:00 [accepted]
PHST- 2020/04/21 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
PHST- 2020/04/21 06:00 [entrez]
AID - 10.1111/ceo.13763 [doi]
PST - ppublish
SO  - Clin Exp Ophthalmol. 2020 Aug;48(6):767-774. doi: 10.1111/ceo.13763. Epub 2020 
      May 12.